Published in J Clin Microbiol on December 01, 1991
Diarrheagenic Escherichia coli. Clin Microbiol Rev (1998) 30.09
Frequent loss of Shiga-like toxin genes in clinical isolates of Escherichia coli upon subcultivation. Infect Immun (1992) 3.47
Rapid and sensitive method for detection of Shiga-like toxin-producing Escherichia coli in ground beef using the polymerase chain reaction. Appl Environ Microbiol (1992) 3.14
Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains. J Clin Microbiol (1997) 2.98
Shiga-like toxin II-related cytotoxins in Citrobacter freundii strains from humans and beef samples. Infect Immun (1993) 2.47
Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect Immun (1993) 2.38
Detection in Escherichia coli of the genes encoding the major virulence factors, the genes defining the O157:H7 serotype, and components of the type 2 Shiga toxin family by multiplex PCR. J Clin Microbiol (2002) 2.06
Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice. Infect Immun (1996) 2.04
The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol Infect (1993) 2.00
Sorbitol-fermenting Shiga toxin-producing Escherichia coli O157:H(-) strains: epidemiology, phenotypic and molecular characteristics, and microbiological diagnosis. J Clin Microbiol (2001) 1.99
Experimental verocytotoxemia in rabbits. Infect Immun (1992) 1.94
Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice. Infect Immun (1994) 1.72
The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality. Infect Immun (1994) 1.70
Analysis of the enterohemorrhagic Escherichia coli O157 DNA region containing lambdoid phage gene p and Shiga-like toxin structural genes. Appl Environ Microbiol (1996) 1.69
Use of digoxigenin-labelled oligonucleotide DNA probes for VT2 and VT2 human variant genes to differentiate Vero cytotoxin-producing Escherichia coli strains of serogroup O157. J Clin Microbiol (1993) 1.48
Isolation and characterization of sorbitol-fermenting Shiga toxin (Verocytotoxin)-producing Escherichia coli O157:H- strains in the Czech Republic. J Clin Microbiol (1998) 1.45
Impact of free verotoxin testing on epidemiology of diarrhea caused by verotoxin-producing Escherichia coli. J Clin Microbiol (1995) 1.44
Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. Infect Immun (1996) 1.30
Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1. J Clin Microbiol (1994) 1.28
Direct detection of verotoxin-producing Escherichia coli in stool samples by PCR. J Clin Microbiol (1995) 1.18
Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing verotoxins (Shiga toxins) in Escherichia coli. J Clin Microbiol (1999) 1.16
Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Clin Exp Immunol (2000) 1.06
Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun (1994) 1.04
Comparative pathogenicity of Escherichia coli O157 and intimin-negative non-O157 Shiga toxin-producing E coli strains in neonatal pigs. Infect Immun (2003) 1.02
Expression of hemin receptor molecule ChuA is influenced by RfaH in uropathogenic Escherichia coli strain 536. Infect Immun (2001) 1.02
Serotypes and virulence profiles of non-O157 Shiga toxin-producing Escherichia coli isolates from bovine farms. Appl Environ Microbiol (2011) 0.92
Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect Immun (2003) 0.90
Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev (1989) 16.53
Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun (1986) 8.09
Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis (1982) 8.05
Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine. J Bacteriol (1988) 5.43
Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511. Infect Immun (1991) 4.63
Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. Microb Pathog (1990) 3.88
Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun (1988) 2.99
Identification of verotoxin type 2 variant B subunit genes in Escherichia coli by the polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Microbiol (1991) 2.78
Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun (1988) 2.65
Two distinct toxins active on Vero cells from Escherichia coli O157. Lancet (1985) 2.47
Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants. Infect Immun (1990) 2.32
Cloning and nucleotide sequence analysis of the genes determining verocytotoxin production in a porcine edema disease isolate of Escherichia coli. Microb Pathog (1988) 1.97
Purification and some properties of a Vero toxin from a human strain of Escherichia coli that is immunologically related to Shiga-like toxin II (VT2). Microb Pathog (1989) 1.78
Characteristics of verotoxigenic Escherichia coli from pigs. Can J Vet Res (1988) 1.73
Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. J Pediatr (1988) 1.68
Serological differences between verocytotoxin 2 and shiga-like toxin II. Lancet (1988) 1.46
Sensitive receptor-specified enzyme-linked immunosorbent assay for Escherichia coli verocytotoxin. J Clin Microbiol (1989) 1.41
Purification of an Escherichia coli serogroup O157:H7 verotoxin and its detection in North American hemorrhagic colitis isolates. J Clin Microbiol (1989) 1.03
The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis (1985) 16.43
Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet (1983) 10.11
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
The enterotoxin plasmids of Escherichia coli. J Infect Dis (1974) 9.10
Campylobacter enteritis in children. J Pediatr (1979) 7.78
Bovine reservoir for verotoxin-producing Escherichia coli O157:H7. Lancet (1987) 5.63
Campylobacter enteritis. Can Med Assoc J (1979) 5.14
A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. N Engl J Med (1987) 4.16
Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem (1987) 3.71
Cytotoxic enterotoxin produced by Aeromonas hydrophila: relationship of toxigenic isolates to diarrheal disease. Infect Immun (1979) 3.65
Motility as an intestinal colonization factor for Campylobacter jejuni. J Gen Microbiol (1985) 3.54
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Transmissible plasmids from Campylobacter jejuni. Antimicrob Agents Chemother (1981) 3.05
Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst (1997) 2.88
Evaluation of a blood-free, charcoal-based, selective medium for the isolation of Campylobacter organisms from feces. J Clin Microbiol (1986) 2.79
Sensitive method for detecting low numbers of verotoxin-producing Escherichia coli in mixed cultures by use of colony sweeps and polymyxin extraction of verotoxin. J Clin Microbiol (1985) 2.70
Sequence heterogeneity of the eae gene and detection of verotoxin-producing Escherichia coli using serotype-specific primers. Epidemiol Infect (1994) 2.70
Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J Bacteriol (1987) 2.65
Vero cytotoxigenic Escherichia coli infection in dairy farm families. J Infect Dis (1996) 2.56
The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol (1988) 2.51
Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis. Lancet (1983) 2.44
Antimicrobial susceptibility of Campylobacter jejuni with special reference to resistance patterns of Canadian isolates. Antimicrob Agents Chemother (1981) 2.43
Antimicrobial susceptibility of Campylobacter jejuni and Campylobacter fetus subsp. fetus to eight cephalosporins with special reference to species differentiation. Antimicrob Agents Chemother (1980) 2.38
Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry (1998) 2.38
Distinct binding properties of eaeA-negative verocytotoxin-producing Escherichia coli of serotype O113:H21. Infect Immun (1994) 2.37
Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature (1992) 2.32
In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin. J Clin Invest (1986) 2.31
Cerebral hemispheric asymmetry in humans. Cortical speech zones in 100 adults and 100 infant brains. Arch Neurol (1975) 2.21
The serotype and biotype distribution of clinical isolates of Campylobacter jejuni and Campylobacter coli over a three-year period. J Infect Dis (1983) 2.17
ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol (2001) 2.11
Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr (2009) 2.07
Cloning and expression of the genes specifying Shiga-like toxin production in Escherichia coli H19. J Bacteriol (1986) 2.04
Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J Biol Chem (1997) 2.02
Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost (2005) 1.99
Cloning and nucleotide sequence analysis of the genes determining verocytotoxin production in a porcine edema disease isolate of Escherichia coli. Microb Pathog (1988) 1.97
Application of the Fortner principle to isolation of Campylobacter from stools. J Clin Microbiol (1979) 1.96
Experimental verocytotoxemia in rabbits. Infect Immun (1992) 1.94
Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem (1989) 1.88
Plasmid-mediated ampicillin resistance in Haemophilus ducreyi. Antimicrob Agents Chemother (1979) 1.85
Haemophilus influenzae: comparison of respiratory tract isolates with genitourinary tract isolates. J Clin Microbiol (1982) 1.80
Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest (1992) 1.80
Structural basis for the conducting interface between LaAlO3 and SrTiO3. Phys Rev Lett (2007) 1.76
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res (1997) 1.74
Characterization of a bacteriophage that carries the genes for production of Shiga-like toxin 1 in Escherichia coli. J Bacteriol (1987) 1.74
Evaluation of Roche Amplicor PCR assay for Mycobacterium tuberculosis. J Clin Microbiol (1996) 1.70
Evolution of enterohemorrhagic Escherichia coli hemolysin plasmids and the locus for enterocyte effacement in shiga toxin-producing E. coli. Infect Immun (1998) 1.68
Attempts to transmit campylobacter enteritis to dogs and cats. Can Med Assoc J (1978) 1.66
A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med (1979) 1.64
Direct isolation of atypical thermophilic Campylobacter species from human feces on selective agar medium. J Clin Microbiol (1989) 1.62
Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy. J Natl Cancer Inst (1996) 1.60
A maternal diet high in n - 6 polyunsaturated fats alters mammary gland development, puberty onset, and breast cancer risk among female rat offspring. Proc Natl Acad Sci U S A (1997) 1.60
C-terminal deletion mutants of the FokI restriction endonuclease. Gene (1993) 1.58
Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem (1991) 1.53
Plasmid-mediated sulfonamide resistance in Haemophilus ducreyi. Antimicrob Agents Chemother (1982) 1.50
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med (2014) 1.48
Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men. J Intern Med (2010) 1.47
Serological differences between verocytotoxin 2 and shiga-like toxin II. Lancet (1988) 1.46
Isolation and characterization of sorbitol-fermenting Shiga toxin (Verocytotoxin)-producing Escherichia coli O157:H- strains in the Czech Republic. J Clin Microbiol (1998) 1.45
Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit. Proc Natl Acad Sci U S A (1992) 1.43
Campylobacter pyloridis is associated with acid-peptic disease in Toronto. Can J Surg (1986) 1.42
Coherent control of pulsed X-ray beams. Nature (2001) 1.41
Homocysteine and brain atrophy on MRI of non-demented elderly. Brain (2003) 1.40
Holistic vets must prove their treatments. Aust Vet J (2001) 1.40
Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol (2000) 1.37
On the constancy of the number of villi in the duodenum of the post-embryonic domestic fowl. J Embryol Exp Morphol (1967) 1.37
Vestibular control of sympathetic activity. An otolith-sympathetic reflex in humans. Exp Brain Res (2002) 1.36
Antigenic heterogeneity of Escherichia coli verotoxins. Lancet (1986) 1.35
From the National Institutes of Health. Summary of the International Symposium and Workshop on Infections due to Verocytotoxin (Shiga-like toxin)-producing Escherichia coli. J Infect Dis (1988) 1.34
Human Escherichia coli O157:H7 infection associated with the consumption of unpasteurized goat's milk. Epidemiol Infect (1997) 1.34
ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer (2003) 1.32
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res (1993) 1.32
Characterization of the human and mouse HEY1, HEY2, and HEYL genes: cloning, mapping, and mutation screening of a new bHLH gene family. Genomics (2000) 1.30
Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer (1999) 1.30
Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1. J Clin Microbiol (1994) 1.28
Mitomycin-induced synthesis of a Shiga-like toxin from enteropathogenic Escherichia coli H.I.8. Infect Immun (1993) 1.27
Free healthy breakfasts in primary schools: a cluster randomised controlled trial of a policy intervention in Wales, UK. Public Health Nutr (2010) 1.24
Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology (2002) 1.24
Abortion and perinatal sepsis associated with campylobacter infection. Rev Infect Dis (1986) 1.22
Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep (1999) 1.19
Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol (2001) 1.18
Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents. J Clin Microbiol (1996) 1.18
Approaches to working in high-dimensional data spaces: gene expression microarrays. Br J Cancer (2008) 1.17
From collaboration to commissioning: developing relationships between primary health and social services. BMJ (1998) 1.17
Rapid oxidation in vitro of endogenous and exogenous glutathione in bile of rats. J Biol Chem (1981) 1.16
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br J Cancer (1996) 1.16
Asking pregnant women about HIV risk. N Z Med J (1998) 1.14
Isolation of environmental mycobacteria from clinical specimens in south-east England: 1973-1993. Int J Tuberc Lung Dis (1997) 1.13
Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect Immun (1997) 1.12
Transmissible tetracycline resistance in Campylobacter jejuni. Lancet (1980) 1.12
Pathogenesis of haemolytic uraemic syndrome. Lancet (1987) 1.12
Infectious agents in acute respiratory disease in horses in Ontario. J Vet Diagn Invest (1997) 1.11
Translocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. Am J Physiol (1997) 1.10